Editorial Board
Associate Editors
Section on Clinical Immunology
Lionel Apetoh, PhD, Brown Center for Immunotherapy Immune Monitoring Core, Indiana University School of Medicine, United States of America
Prof. Lionel Apetoh earned his MSc from the University of Strasbourg in 2004. Upon graduation, he continued his education at the University of Paris XI where he earned his Ph.D. in immunology in 2008. At Indiana University (IU), Dr. Apetoh serves as a professor of microbiology and immunology and the director of the Brown Center for Immunotherapy Immune Monitoring Core. In 2023, he was awarded the additional, honorary title of Christopher Brown Professor of Immunology.
Prior to joining the IU faculty, Dr. Apetoh held positions at INSERM in Dijon, France, and the University of Tours in France. Dr. Apetoh’s current research focuses on the investigation of the relationship between T lymphocytes and anticancer immune responses. He has authored over 120 research publications related to this topic.
Throughout his robust research and teaching career, Dr. Apetoh has received several awards and honors from internationally recognized organizations. He earned the Platet-Mathieu Prize from the Academie Des Sciences, Belles-Lettres et Arts de Lyon in 2017. In 2015, he was also awarded an ERC Starting Grant, the Albert Sézary Prize from the French National Academy of Medicine, and the Olga Sain Prize from the Ligue Contre le Cancer.
Section on Immunogenetics
Susan Schlenner, PhD, Laboratory of Adaptive Immunity, Department of Microbiology, Immunology and Transplantation, KU Leuven, Belgium
Susan Schlenner graduated in Biology in 2003, and obtained a PhD in Immunology from the University of Ulm in Germany in 2009. Her PhD studies were focused on Mast cell biology as well as T cell development. Thereafter, Dr Schlenner moved to the Dana-Farber Cancer Institute/Harvard Medical School, Boston, to conduct her postdoctoral research in the area of regulatory T cell biology until 2012. She continued studying regulatory T cells and autoimmune conditions at the KU Leuven, Belgium, as senior scientist. In 2017, she was recruited as Research Professor to the Department of Microbiology, Immunology and Transplantation at KU Leuven to establish her research program and group. Since then, her research encompasses the study of regulatory T cell biology and function, the development of biological and chemical drugs for the targeting of Treg in (auto-)inflammatory disease, and the role of the RNA modification pseudouridine in innate and adaptive immune cells.
Section on Single-Cell Omics
Dr. Ramanuj DasGupta, Laboratory of Precision Oncology & Cancer Evolution, Spatial and Single Cell Systems, Genome Institute of Singapore, A*STAR, Singapore
Dr. DasGupta graduated with a double Bachelor’s degree, in Chemistry (B.Sc. Hons., University of Delhi, India, 1994), and in Genetics (B.A., Cambridge University, UK, 1996). He obtained his Ph. D. in Developmental Biology and Molecular Medicine from the University of Chicago, 2002. Thereafter, Dr. DasGupta moved to the Harvard Medical School, Boston to conduct his postdoctoral research where he pioneered whole genome high-throughput functional screens to identify novel regulators of cell-signalling pathways using RNAi technology. Between 2005-2014 Dr. DasGupta established his own research program at the NYU-Cancer Institute, where he rose to the rank of Associate Professor. In 2014, Dr. DasGupta moved to the Genome Institute of Singapore (GIS) where currently he serves as a Senior Group Leader and leads the program in Precision Oncology and Cancer Evolution. The major focus of his program is to define the mechanistic basis for spatio-temporal cross-regulatory interactions between tumor cells and their microenvironment (TME), that drive cellular plasticity and intra-tumor phenotypic heterogeneity, both during tumorigenesis and tumor progression to treatment resistant, metastatic disease.
Section on Translational Immunology
Dr. Yanling Xiao, MD, PhD, Immunology Department, Leiden University Medical Center, Netherlands
Yanling Xiao, obtained MD degree from Tongji Medical University in China and PhD degree (on the topic of mucosal immunity) from Oita Medical University in Japan. From 1999 to 2019, Dr. Xiao worked in the Division of Tumor Biology and Immunology of the Netherlands Cancer Institute as postdoc/senior scientist and then as associated staff scientist. In 2014 Dr. Xiao took a sabbatical in the Department of Pathology of Stanford University as visiting faculty member. Since 2019, Dr. Xiao joined Immunology Department of the Netherlands Leiden University Medical Center as assistant professor. The focus of Dr. Xiao’s research is DC/T-cell communication in cancer & DC-centric tumor immunology.
Board Members
Santanu Bose, PhD, Washington State University, Pullmann, WA, United States of America
Jay Bream, John Hopkins Bloomberg School of Public Health, Baltimore, MD, United States of America
Sandra D'Alfonso, Universitá del Piemonte Orientale A. Avogadro, Novara, Italy
Raymond Donnelly, PhD, Food and Drug Administration FDA, Silver Spring, MD, United States of America
Mehmet Tevfik Dorak, MD, PhD, Kingston University, London, United Kingdom
Sarah Dunstan, PhD, The University of Melbourne, Melbourne, VIC, Australia
Lorenzo Galluzzi, Weill Cornell Medical College, New York, NY, United States of America
Douglas Green, PhD, St. Jude Children's Research Hospital, Memphis, TN, United States of America
Philippe Gros, PhD, McGill University, Montreal, QC, Canada
Percio Gulko, MD, Icahn School of Medicine at Mount Sinai, New York, NY, United States of America
Niels Halama, MD, German Cancer Research Center, Heidelberg, Germany
Rune Hartmann, Aarhus University, Aarhus, Denmark
Niels Hellings, PhD, BIOMED Institute, Hasselt University, Hasselt, Belgium
Holger Heyn, PhD, National Center for Genomic Analysis, Barcelona, Spain
Ping-Chih Ho, University of Lausanne, Lausanne, Switzerland
Matteo Iannacone, MD, PhD, San Raffaele Scientific Institute and University, San Raffaele, Italy
Oliver Kepp, PhD, National Institute of Health and Medical Research INSERM, Paris, France
Guido Kroemer, MD, PhD, University of Paris Cité, Paris Hospitals, Gustave Roussy Institute, Paris, France
Wilson Liao, University of California, San Francisco, CA, United States of America
Xiaojing Ma, PhD, Weill Cornell Medicine, New York, NY, United States of America
Laura Mackay, FAHMS, PhD, University of Melbourne, Melbourne, VIC, Australia
Massimiliano Mazzone, VIB Center for Cancer Biology, University of Leuven, Leuven, Belgium
Xavier Montagutelli, DVM, PhD, Pasteur Institute, Paris, France
Grant Morahan, PhD, CAMS Institute of Laboratory Animal Sciences, Beijing, China, The Harry Perkins Institute of Medical Research, University of Western Australia, University of Melbourne, Crawley, WA, Australia
Narayanan Parameswaran, Michigan State University, East Lansing, MI, United States of America
Woong-Yang Park, Samsung Genome Institute, Seoul, South Korea
Brian Ruffel, PhD, H. Lee Moffitt Cancer Center, Tampa, FL, United States of America
Christian Seitz, University of Tuebingen, Tübingen, Germany
Dmitry Shayakhmetov, PhD, Emory University, Atlanta, GA, United States of America
Antonella Sistigu, PhD, Catholic University of the Sacred Heart, Milan, Italy
Ludvig Magne Sollid, University of Oslo, Oslo, Norway
Catherine Stein, PhD, Case Western Reserve University, Cleveland, OH, United States of America
Iain Tan Bee Huat, National Cancer Centre, Singapore
Jianming Tang, PhD, University of Alabama, Birmingham, AL, United States of America
Pierre van der Bruggen, de Duve Institute, Lambert Belgium, Belgium
Darren Woodside, PhD, The Texas Heart Institute, Houston, TX, United States of America
Samuel Workenhe, DVM, PhD, University of Guelph, Guelph, ON, Canada
